SLC5A2 and hydrops fetalis: SGLT2-Is reduced composite CV death or first hospitalization for HF, CV death, first hospitalization for HF, and all-cause mortality; these results were consistently observed across all five trials, supporting the role of SGLT2-Is as a fundamental therapy for HF irrespective of ejection fraction or care setting.